ArticleEuropean radiology2026
Prognostic value of body composition on early recurrence and long-term survival of resectable pancreatic ductal adenocarcinoma.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Correlation of Computed Tomography (CT)-Based Body Composition and Survival in Pancreatic Cancer Patients: A Systematic Review.Tomography (Ann Arbor, Mich.) · 2026Pooled it
- Pancreatic Steatosis and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Systematic Review of the Current Evidence.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo explore the associations of CT-evaluated body composition with early recurrence (ER) and overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC) after resection. MATERIALS AND
methodsA retrospective analysis was performed on consecutively enrolled patients who underwent surgical resection for PDAC between 2014 and 2023. Patients were divided into a training set (n = 412) and a validation set (n = 120). Sex-specific cutoff values were determined for body composition indices, including visceral-to-subcutaneous fat ratio (VSR), skeletal muscle density (SMD), subcutaneous fat area (SFA), and other metrics. Logistic regression and Cox proportional hazards models were used to analyze the associations of body composition with ER and OS. Subgroup analyses were conducted based on clinicopathological characteristics to explore the prognostic value of body composition.
resultsHigh VSR was an independent predictor for ER (OR: 2.304, p = 0.001) and worse OS (HR: 1.462, p = 0.007), whereas high SMD (HR: 0.609, p = 0.005) and high SFA (HR: 0.649, p = 0.002) were independent predictors for better OS. Subgroup analyses revealed variations in the prognostic effect of VSR according to diabetes status and tumor size. A model combining body composition metrics and clinicopathological indicators (carbohydrate antigen 19-9, carbohydrate antigen 12-5, tumor-node-metastasis stage, lymphovascular invasion, and adjuvant therapy) demonstrated good predictive ability for ER, with AUCs of 0.80 in the training set and 0.82 in the validation set.
conclusionHigh VSR was an independent predictor for ER and worse OS in PDAC. Moreover, combining body composition metrics and clinicopathological indicators can improve the prognosis prediction of patients with PDAC after surgery. KEY POINTS: Question What are the associations of CT-evaluated body composition with early recurrence and overall survival in patients with pancreatic ductal adenocarcinoma after resection? Findings High visceral-to-subcutaneous fat ratio is an independent predictor for early recurrence, whereas high skeletal muscle density and subcutaneous fat area independently predict better overall survival. Clinical relevance Combining body composition and clinicopathological indicators (carbohydrate antigen 19-9, carbohydrate antigen 12-5, tumor-node-metastasis stage, lymphovascular invasion, and adjuvant therapy) enables reliable prediction of postoperative prognosis in pancreatic ductal adenocarcinoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.